IP Library Granted Patent US 7,009,024
Granted Patent B2
US 7,009,024 · App. 10/666,143 · Granted Mar 7, 2006

High refractive index aromatic-based siloxane difunctional macromonomers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,009,024
App. No.
10/666,143
Granted
Mar 7, 2006
Kind
B2
Abstract

Optically transparent, relatively high refractive index polymeric compositions and ophthalmic devices such as intraocular lenses, corneal inlays and contact lenses made therefrom are described herein. The preferred polymeric compositions are produced through the polymerization of one or more aromatic-based siloxane macromonomers or the copolymerization of one or more aromatic-based siloxane macromonomers with one or more non-siloxy aromatic-based monomers, non-aromatic-based hydrophobic monomers or non-aromatic-based hydrophilic monomers.

Claims (20)

1. A method of using an ophthalmic device manufactured using polymeric compositions, said method comprising:

implanting said ophthalmic device within an eye;

wherein said polymeric compositions are produced through a polymerization of one or more aromatic-based siloxane macromonomers having a formula of

wherein the R groups are the same or different aromatic-based substituents; each R group is selected from the group consisting of

R 1 is an aromatic-based substituent or an alkyl; x is a non-negative integer, and y and u are natural numbers; said ophthalmic device is manufactured by casting said one or more polymeric compositions in the form of a rod; lathing or machining said rod into disks; and lathing or machining said disks into ophthalmic devices.

2. A method of using an ophthalmic device manufactured using polymeric compositions, said method comprising:

implanting said ophthalmic device within an eye; wherein said polymeric compositions are produced through a polymerization of one or more aromatic-based siloxane macromonomers having a formula of

wherein the R groups are the same or different aromatic-based substituents; each R group is selected from the group consisting of

R 1 is an aromatic-based substituent or an alkyl; x is a non-negative integer; and y and u are natural numbers; said ophthalmic device is manufactured by pouring said one or more polymeric compositions into a mold prior to curing; curing said one or more polymeric compositions; and removing said one or more polymeric compositions from said mold following curing thereof.

3. The method of claim 1 or 2 wherein said ophthalmic device is an intraocular lens or corneal inlay.

4. A method of using an ophthalmic device manufactured using polymeric compositions, said method comprising:

implanting said ophthalmic device within an eye;

wherein said polymeric compositions are produced through a polymerization of one or more aromatic-based siloxane macromonomers having a formula of

wherein the R groups are the same or different aromatic-based substituents; each R group comprises an aromatic group having a linking group that covalently attaches the aromatic group to a silicon atom; R 1 is an aromatic-based substituent or an alkyl; x is a non-negative integer and y and u are natural numbers; said ophthalmic device is manufactured by casting said one or more polymeric compositions in the form of a rod; lathing or machining said rod into disks; and lathing or machining said disks into ophthalmic devices; and wherein an attachment of the aromatic group to the silicon atom results from a hydrosilylation of an allylic functional group on the aromatic group.

5. The method of claim 4 , wherein said ophthalmic device is an intraocular lens or a corneal inlay.

6. A method of using an ophthalmic device manufactured using polymeric compositions, said method comprising:

implanting said ophthalmic device within an eye;

wherein said polymeric compositions are produced through a polymerization of one or more aromatic-based siloxane macromonomers having a formula of

wherein the R groups are the same or different aromatic-based substituents; each R group each R group comprises an aromatic group having a linking group that covalently attaches the aromatic group to a silicon atom; R 1 is an aromatic-based substituent or an alkyl; x is a non-negative integer; and y and u are natural numbers; said ophthalmic device is manufactured by pouring said one or more polymeric compositions into a mold prior to curing; curing said one or more polymeric compositions; and removing said one or more polymeric compositions from said mold following curing thereof; and wherein an attachment of the aromatic group to the silicon atom results from a hydrosilylation of an allylic functional group on the aromatic group.

7. The method of claim 6 , wherein said ophthalmic device is an intraocular lens or a corneal inlay.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →